Loading data for ABT — first visit, this takes a few seconds.

알림

Abbott Laboratories (ABT)

NYSE: ABT · 실시간 가격 · USD

112.68

+2.31 (2.09%)

종가 기준: Aug 18, 2026, 8:01 PM

2.09% (1D)

데이터 없음

매수호가	n/a
시가총액	194.98B
매출 (ttm)	46.58B
순이익 (ttm)	5.4B
베타	0.58
EPS (ttm)	3.16
P/E (ttm)	35.66
선행 P/E	18.58
P/B (ttm)	3.81
P/S (ttm)	4.21
Earnings Date	Oct 14, 2026

매도호가	n/a
거래량	5,318,410
평균 거래량 (20일)	12,011,344
시가	112.45
전일 종가	110.37
일중 범위	111.75 - 113.63
52주 범위	81.97 - 137.49
애널리스트	n/a
목표주가	n/a
배당	$2.52 (2.24%)
배당락일	2026년 7월 15일

ABT 소개

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms...

[더 보기]

산업 Medical Devices

섹터 Healthcare

IPO 일자 Mar 17, 1980

직원 수 122,000

상장 거래소 NYSE

티커 ABT

웹사이트 https://www.abbott.com

전체 기업 정보

재무 실적

2025년 Abbott Laboratories의 매출은 44.33B로, 전년 41.95B 대비 5.67% 증가했습니다. 순이익은 6.52B로, -51.32% 감소했습니다.

재무제표

어닝 서프라이즈

Abbott Laboratories가 Jul 16, 2026에 분기 실적을 발표했습니다:

매출 n/a 예상치 하회 $0, 및 -100.00% 전년 대비 감소.

EPS 1.31 예상치 상회 0.03, 및 3.97% 전년 대비 성장.

다음 실적 발표

Abbott Laboratories의 실적 발표 예정일은 Oct 14, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1일 전 · Simply Wall St.

Abbott (ABT) Stock Looks Reasonable On Earnings With Stronger Cash Flow

Abbott Laboratories stock has delivered a 14.0% total return over the past three years, yet its current checks suggest a mixed valuation picture as the Discounted Cash Flow (DCF) estimate points to me...

1일 전 · Motley Fool

If You Invest $100 a Month in SCHD, Here's the Passive Income It Could Deliver in 20 Years

This top dividend ETF is still a reliable long-term income investment.

1일 전 · Simply Wall St.

What Does Abbott Laboratories (ABT) Gain From This New App Controlled Pump Rollout?

Abbott Laboratories (NYSE:ABT) is supplying its Instinct sensor for MiniMed's newly shipped app-controlled insulin pump in the U.S. The system pairs what MiniMed describes as the world's smallest app-...

1일 전 · Zacks

QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns

QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.

1일 전 · Zacks

Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

2 페이지 중 1

Abbott Laboratories (ABT)